Telomelysin - Oncolys Biopharma

Drug Profile

Telomelysin - Oncolys Biopharma

Alternative Names: OBP-301; Telomelysin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncolys Biopharma
  • Developer Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses; Viral proteins
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Head and neck cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma
  • No development reported Adenoid-cystic-carcinoma; Breast cancer; Mesothelioma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Adenoid cystic carcinoma in USA (Intratumoural, Injection)
  • 01 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Intratumoural) (NCT03172819)
  • 07 Jul 2017 Oncolys BioPharma enrols the first patient in a phase I trial for Oesophageal cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top